collection
MENU ▼
Read by QxMD icon Read
search

lymphoma

shared collection
5 papers 0 to 25 followers
https://www.readbyqxmd.com/read/27071634/therapeutic-options-in-peripheral-t-cell-lymphoma
#1
REVIEW
Yaping Zhang, Wei Xu, Hong Liu, Jianyong Li
Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. With the exception of low-risk anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), the majority of patients relapse rapidly; the current 5-year overall survival rates are only 10-30%. Novel targeted therapies and combination chemotherapies are required for the treatment of patients with PTCL...
April 12, 2016: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/22783355/epidemiologic-overview-of-malignant-lymphoma
#2
Jooryung Huh
Malignant lymphoma encompasses a wide variety of distinct disease entities. It is generally more common in developed countries and less common in developing countries. The East Asia region has one of the lowest incidence rates of malignant lymphoma. The incidence of malignant lymphoma around the world has been increasing at a rate of 3-4% over the last 4 decades, while some stabilization has been observed in developed countries in recent years. The reasons behind this lymphoma epidemic are poorly understood, although improving diagnostic accuracy, the recent AIDS epidemic, an aging world population and the increasing adoption of cancer-causing behaviors are suggested as contributing factors...
June 2012: Korean Journal of Hematology
https://www.readbyqxmd.com/read/9926240/beacopp-a-new-regimen-for-advanced-hodgkin-s-disease-german-hodgkin-s-lymphoma-study-group
#3
REVIEW
V Diehl, J Franklin, D Hasenclever, H Tesch, M Pfreundschuh, B Lathan, U Paulus, M Sieber, J U Rüffer, M Sextro, A Engert, J Wolf, R Hermann, L Holmer, U Stappert-Jahn, E Winnerlein-Trump, G Wulf, S Krause, A Glunz, K von Kalle, H Bischoff, C Haedicke, E Dühmke, A Georgii, M Loeffler
The BEACOPP chemotherapy regimen for advanced Hodgkin's disease employs a rearranged schedule permitting a shortened three-week cycle. With haematological growth factor support, the dosages of cyclophosphamide, etoposide and adriamycin could be moderately escalated. The 3-armed multicentre HD9 trial (recruitment 1993-1998; 1300 patients randomised) aimed to compare BEACOPP with the standard COPP/ABVD chemotherapy and to detect and measure the gain in efficacy, if any, due to moderate dose escalation of BEACOPP...
1998: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/26891458/the-impact-of-comorbidity-on-cancer-and-its-treatment
#4
REVIEW
Diana Sarfati, Bogda Koczwara, Christopher Jackson
Answer questions and earn CME/CNE Comorbidity is common among cancer patients and, with an aging population, is becoming more so. Comorbidity potentially affects the development, stage at diagnosis, treatment, and outcomes of people with cancer. Despite the intimate relationship between comorbidity and cancer, there is limited consensus on how to record, interpret, or manage comorbidity in the context of cancer, with the result that patients who have comorbidity are less likely to receive treatment with curative intent...
July 2016: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/23375551/diffuse-large-b-cell-lymphoma
#5
REVIEW
Maurizio Martelli, Andrés J M Ferreri, Claudio Agostinelli, Alice Di Rocco, Michael Pfreundschuh, Stefano A Pileri
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for 31% of all NHL in Western Countries. Following, morphological, biological and clinical studies have allowed the subdivision of DLBCLs into morphological variants, molecular and immunophenotypic subgroups and distinct disease entities. However, a large number of cases still remain biologically and clinically heterogeneous, for which there are no clear and accepted criteria for subclassification; these are collectively termed DLBCL, not otherwise specified (NOS)...
August 2013: Critical Reviews in Oncology/hematology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"